COSCIENS Biopharma Inc.
CSCI · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $9 | $14 | $16 | $20 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $3 | $2 | $2 | $2 |
| Inventory | $2 | $2 | $3 | $3 |
| Other Curr. Assets | $3 | $2 | $2 | $3 |
| Total Curr. Assets | $17 | $20 | $24 | $28 |
| Property Plant & Equip (Net) | $11 | $11 | $11 | $12 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $2 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $1 |
| Other NC Assets | -$0 | $0 | $0 | $1 |
| Total NC Assets | $11 | $11 | $11 | $16 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $28 | $31 | $35 | $44 |
| Liabilities | – | – | – | – |
| Payables | $2 | $3 | $2 | $2 |
| Short-Term Debt | $0 | $1 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $3 | $4 | $4 | $5 |
| Total Curr. Liab. | $6 | $7 | $7 | $8 |
| LT Debt | $2 | $2 | $2 | $1 |
| Deferred Rev, NC | $1 | $1 | $1 | $2 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $12 | $11 | $12 | $12 |
| Total NC Liab. | $15 | $14 | $15 | $16 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $2 | $2 | $2 | $2 |
| Total Liabilities | $20 | $21 | $22 | $24 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $23 | $23 | $22 | $22 |
| Retained Earnings | -$17 | -$15 | -$12 | -$5 |
| AOCI | -$2 | -$2 | -$1 | -$2 |
| Other Equity | $4 | $4 | $4 | $4 |
| Total Equity | $7 | $10 | $13 | $20 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $28 | $31 | $35 | $44 |
| Net Debt | -$7 | -$11 | -$14 | -$18 |